Monday Nov 25
The Motley Fool
3 New Breast Cancer Treatments Worth Watching
Here come the new challengers Novartis, Pfizer, and Eli Lilly are racing against each other to launch a new class of breast-cancer treatments known as CDK inhibitors.
Generic drugs play a central role in reining in health care spending
It was a huge relief to Carol Thompson in 2011 when her breast cancer drug Femara went off patent and became available in a generic version.
Biomarker Helps Predict Breast Cancer Recurrence
The Massachusetts General Hospital Cancer Center investigators describe finding that the HOXB13/IL17BR ratio can indicate which women are at risk for cancer recurrence after tamoxifen and which are most likely to benefit from continuing treatment with the aromatase inhibitor letrozole .
Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor -positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.
The Miami Herald
Pfizer breast cancer drug gets breakthrough label
Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.